Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zepatier

- PMLiVE

FDA to review Merck & Co’s allergy immunotherapy

Accepts application for oral tablet to protect against ragweed-based allergies

- PMLiVE

AbbVie gets ‘breakthrough’ status for hepatitis C regimen

Combination could be all-oral alternative to injectable interferon alpha-based therapies

- PMLiVE

Merck & Co wins green light in US for Zetia-Lipitor combo

Vytorin extension wins FDA approval

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

Roche - Basel

Roche taps local expertise for hep C drug in China

Partners with Chinese-American biotech company Ascletis

- PMLiVE

Gilead files oral hepatitis C drug sofosbuvir in US

Could be part of first all-oral regimen for virus

Merck & Co’s Jürgen Polifka joins Cardiome

Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess

- PMLiVE

BMS and Vertex partner on oral hepatitis treatment

Will investigate combination of daclatasvir and VX-135

- PMLiVE

Merck & Co fails to block generic Januvia in India

Court says Glenmark can sell cheap copy of diabetes drug

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links